EMR-话题@MedSci

#EMR#

26篇内容 | 2040人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1738705, encodeId=258e1e3870527, content=<a href='/topic/show?id=ac106e33e1' target=_blank style='color:#2F92EE;'>#EMR#</a>, objectTitle=DDW 2016：EMR后粘膜缺损切缘热消融可显著减少腺瘤复发, objectType=article, longId=70855, objectId=37a6e0855c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37a6e0855c5, replyNumber=0, likeNumber=90, createdTime=2017-01-02, rootId=0, userName=ms1292405679162969, userId=944034484276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37a6e0855c5, moduleTitle=DDW 2016：EMR后粘膜缺损切缘热消融可显著减少腺瘤复发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37a6e0855c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738702, encodeId=d2131e38702a8, content=<a href='/topic/show?id=ac106e33e1' target=_blank style='color:#2F92EE;'>#EMR#</a>, objectTitle=STM：birinapant和emricasan新的药物组合在治疗白血病上显示成功的希望, objectType=article, longId=68846, objectId=e02468846d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e02468846d4, replyNumber=0, likeNumber=51, createdTime=2016-08-22, rootId=0, userName=ms1292405679162969, userId=944034484276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e02468846d4, moduleTitle=STM：birinapant和emricasan新的药物组合在治疗白血病上显示成功的希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e02468846d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738706, encodeId=d87d1e38706c5, content=<a href='/topic/show?id=ac106e33e1' target=_blank style='color:#2F92EE;'>#EMR#</a>, objectTitle=喜讯！FDA授予罗氏抗炎药Actemra/RoActemra第2个突破性药物资格，治疗巨细胞动脉炎（GCA）, objectType=article, longId=79382, objectId=ddb5e9382a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddb5e9382a1, replyNumber=0, likeNumber=99, createdTime=2017-05-07, rootId=0, userName=ms1292405679162969, userId=944034484276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddb5e9382a1, moduleTitle=喜讯！FDA授予罗氏抗炎药Actemra/RoActemra第2个突破性药物资格，治疗巨细胞动脉炎（GCA）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddb5e9382a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738701, encodeId=b6521e38701aa, content=<a href='/topic/show?id=ac106e33e1' target=_blank style='color:#2F92EE;'>#EMR#</a>, objectTitle=CHMP建议批准罗氏皮下注射剂型RoACTEMRA, objectType=article, longId=28635, objectId=eafc28635ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eafc28635ec, replyNumber=0, likeNumber=51, createdTime=2014-03-02, rootId=0, userName=ms1292405679162969, userId=944034484276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eafc28635ec, moduleTitle=CHMP建议批准罗氏皮下注射剂型RoACTEMRA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eafc28635ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738699, encodeId=b3d31e38699fe, content=<a href='/topic/show?id=ac106e33e1' target=_blank style='color:#2F92EE;'>#EMR#</a>, objectTitle=肾移植受者H1N1A型流感疫苗佐剂（Pandemrix®）的免疫反应, objectType=article, longId=4724, objectId=8edf4e2479, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8edf4e2479, replyNumber=0, likeNumber=65, createdTime=2013-01-26, rootId=0, userName=ms1292405679162969, userId=944034484276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8edf4e2479, moduleTitle=肾移植受者H1N1A型流感疫苗佐剂（Pandemrix®）的免疫反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8edf4e2479)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738700, encodeId=face1e387009e, content=<a href='/topic/show?id=ac106e33e1' target=_blank style='color:#2F92EE;'>#EMR#</a>, objectTitle=Genentech风湿性关节炎药物Actemra在Brevacta试验中达主要终末点, objectType=article, longId=8435, objectId=deaf8435cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=deaf8435cd, replyNumber=0, likeNumber=68, createdTime=2012-08-13, rootId=0, userName=ms1292405679162969, userId=944034484276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=deaf8435cd, moduleTitle=Genentech风湿性关节炎药物Actemra在Brevacta试验中达主要终末点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=deaf8435cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

EMR

2020-05-29

ms1292405679162969 (审核中...)

前往app查看评论内容

#EMR#

DDW 2016：EMR后粘膜缺损切缘热消融可显著减少腺瘤复发

2017-01-02

ms1292405679162969 (审核中...)

前往app查看评论内容

#EMR#

STM：birinapant和emricasan新的药物组合在治疗白血病上显示成功的希望

2016-08-22

ms1292405679162969 (审核中...)

前往app查看评论内容

#EMR#

喜讯！FDA授予罗氏抗炎药Actemra/RoActemra第2个突破性药物资格，治疗巨细胞动脉炎（GCA）

2017-05-07

ms1292405679162969 (审核中...)

前往app查看评论内容

#EMR#

CHMP建议批准罗氏皮下注射剂型RoACTEMRA

2014-03-02

ms1292405679162969 (审核中...)

前往app查看评论内容

#EMR#

肾移植受者H1N1A型流感疫苗佐剂（Pandemrix®）的免疫反应

2013-01-26

ms1292405679162969 (审核中...)

前往app查看评论内容

#EMR#

Genentech风湿性关节炎药物Actemra在Brevacta试验中达主要终末点

2012-08-13

科室
- - 订阅+
  - 更多科室
工具
服务